These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36268410)

  • 1. Kyzatrex - Oral testosterone replacement therapy.
    Asghar AA; Hashmi MR; Ahmed R; Khabir Y
    Ann Med Surg (Lond); 2022 Oct; 82():104625. PubMed ID: 36268410
    [No Abstract]   [Full Text] [Related]  

  • 2. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism.
    DelConte A; Papangkorn K; Kim K; Bruno BJ; Chidambaram N; Khera M; Goldstein I; Kohler TS; Miner M; Dobs AS; Patel MV
    Andrology; 2022 May; 10(4):669-676. PubMed ID: 34994093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with transdermal testosterone replacement therapy for hypogonadal men.
    Parker S; Armitage M
    Clin Endocrinol (Oxf); 1999 Jan; 50(1):57-62. PubMed ID: 10341856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of estrogen and androgen levels after oral estrogen replacement therapy.
    Slater CC; Zhang C; Hodis HN; Mack WJ; Boostanfar R; Shoupe D; Paulson RJ; Stanczyk FZ
    J Reprod Med; 2001 Dec; 46(12):1052-6. PubMed ID: 11789085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Oral Testosterone the New Frontier of Testosterone Replacement Therapy?
    Ahmad SW; Molfetto G; Montoya D; Camero A
    Cureus; 2022 Aug; 14(8):e27796. PubMed ID: 36106278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous testosterone replacement therapy versus raising endogenous testosterone levels: current and future prospects.
    Khodamoradi K; Khosravizadeh Z; Parmar M; Kuchakulla M; Ramasamy R; Arora H
    F S Rev; 2021 Jan; 2(1):32-42. PubMed ID: 33615283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues Surrounding Testosterone Replacement Therapy.
    Schlich C; Romanelli F
    Hosp Pharm; 2016 Oct; 51(9):712-720. PubMed ID: 27803500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis.
    Kang DY; Li HJ
    Medicine (Baltimore); 2015 Jan; 94(3):e410. PubMed ID: 25621688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens.
    Savvas M; Studd JW; Norman S; Leather AT; Garnett TJ; Fogelman I
    Br J Obstet Gynaecol; 1992 Sep; 99(9):757-60. PubMed ID: 1420016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-sectional analysis of testosterone therapies in hypopituitary men on stable pituitary hormone replacement.
    Siyambalapitiya S; Jonsson P; Koltowska-Haggstrom M; Gaillard R; Ho K; Ross RJ
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):907-13. PubMed ID: 18823394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-hormone binding globulin as an indicator of the hepatic impacts of continuous combined hormone replacement regimens.
    Raudaskoski T; Laatikainen T; Kauppila A
    Maturitas; 1998 May; 29(1):87-92. PubMed ID: 9643521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone deficiency and replacement.
    Howell S; Shalet S
    Horm Res; 2001; 56 Suppl 1():86-92. PubMed ID: 11786693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of testosterone replacement therapy.
    Hameed A; Brothwood T; Bouloux P
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1213-9. PubMed ID: 14649214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
    Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
    Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between testosterone and growth hormone on whole-body protein anabolism occurs in the liver.
    Birzniece V; Meinhardt UJ; Umpleby MA; Handelsman DJ; Ho KK
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1060-7. PubMed ID: 21239519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The appropriateness and persistence of testosterone replacement therapy in Ontario.
    Martins D; Yao Z; Tadrous M; Shah BR; Juurlink DN; Mamdani MM; Gomes T;
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):119-126. PubMed ID: 27528454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy in male hypogonadism.
    Byrne M; Nieschlag E
    J Endocrinol Invest; 2003 May; 26(5):481-9. PubMed ID: 12906378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials.
    Guo C; Gu W; Liu M; Peng BO; Yao X; Yang B; Zheng J
    Exp Ther Med; 2016 Mar; 11(3):853-863. PubMed ID: 26998003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone replacement treatment options for HIV-infected men.
    Cofrancesco J; Whalen JJ; Dobs AS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Dec; 16(4):254-65. PubMed ID: 9402072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone supplementation for erectile dysfunction: results of a meta-analysis.
    Jain P; Rademaker AW; McVary KT
    J Urol; 2000 Aug; 164(2):371-5. PubMed ID: 10893588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.